DUBLIN–(BUSINESS WIRE)–The “Medical Device CRO Market: Industry Trends and Global Forecasts, Till 2035 – Distribution by Target Therapeutic Area, Scale of OperationDUBLIN–(BUSINESS WIRE)–The “Medical Device CRO Market: Industry Trends and Global Forecasts, Till 2035 – Distribution by Target Therapeutic Area, Scale of Operation

Navigating the $19.3 Billion Medical Device CRO Market, 2025-2035: Mergers and Acquisitions Boost Geographical Consolidation – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Medical Device CRO Market: Industry Trends and Global Forecasts, Till 2035 – Distribution by Target Therapeutic Area, Scale of Operation, Device Class, Type of Clinical Service Offered, Type of Preclinical Service Offered and Key Geographies” has been added to ResearchAndMarkets.com’s offering.

The global medical device CRO market is projected to grow from USD 13.3 billion in the current year to USD 19.3 billion by 2035, driven by a significant CAGR during the forecast period. This growth is largely fueled by the increasing elderly population and the prevalence of chronic illnesses, sparking a demand for innovative medical devices. Since 2020, the USFDA has approved approximately 105 medical devices, with over 35 gaining approval each year. However, the industry faces hurdles, including a complex and resource-demanding product development phase, enhanced by regulatory mandates ensuring medical devices’ safety, which complicate operations for industry leaders.

To navigate these challenges, medical device developers increasingly outsource research activities to specialized CROs, which excel in handling clinical studies, regulatory demands, and safety compliance. These organizations facilitate the transition of innovative concepts to market, efficiently managing the product development lifecycle. The rapid integration of advanced technologies and tools, like risk monitoring systems and cloud computing, is reshaping the medical device landscape, forecasting significant growth for the CRO market in the coming decade.

Key insights from the report reveal that over 590 CROs claim competency in offering diverse research and analytical services for medical devices. The market is notably fragmented, with various players across different regions providing services for a range of device classes. CROs are continuously enhancing their capabilities to better their service offerings, evident in strategic mergers and acquisitions, where 53% target geographical consolidation. Over 14,000 trials involving approximately 4.6 million patients with various conditions are registered worldwide to assess medical devices’ efficacy and accuracy. The market’s steady growth is expected, propelled by stakeholders’ ongoing efforts.

The market segmentation reveals that clinical operations currently command the largest share. Notably, the clinical services sector remains dominant due to rising clinical trials on medical devices. Meanwhile, Class II devices are poised as the fastest-growing segment. In preclinical services, biocompatibility testing emerges as the fastest-growing type, though sterility and microbial testing hold a significant market share. CNS disorders dominate the therapeutic area segment, reflecting a substantial part of the device CRO market. Geographically, North America leads the charge with the largest market share, though other regions are expected to grow at higher CAGRs over the years.

Prominent players within this space include Avania, Charles River Laboratories, CROMSOURCE, CSSi LifeSciences, Eurofins Medical Testing, IQVIA, Medpace, NAMSA, Qserve Group, and WuXi AppTec. The research report, bolstered by conversations with various industry stakeholders, investigates several factors, including market sizing, competitive benchmarking, regulatory landscapes, and clinical trials analysis.

The study addresses critical questions like the number of active companies, leading market players, influencers on market evolution, and market size forecasts. It offers a comprehensive market overview, including SWOT analysis, to guide stakeholders in making informed decisions. Additional benefits include complimentary PPT insights, Excel data packs, and content customization, coupled with report walkthrough sessions for detailed understanding, ensuring stakeholders are well-equipped to navigate and excel in the medical device CRO market.

Key Topics Covered

Section I: Report Overview

1. Preface

2. Research Methodology

3. Market Dynamics

4. Macro-Economic Indicators

Section II: Qualitative Insights

5. Executive Summary

6. Introduction

7. Regulatory and Reimbursement Landscape for Medical Devices

Section III: Competitive Landscape

8. Medical Device Preclinical CROs: Market Landscape

9. Medical Device Clinical CROs: Market Landscape

10. Brand Positioning Analysis: Preclinical Medical Device CROs

11. Competitive Benchmarking: Clinical CROs

Section IV: Company Profiles

12. Company Profiles

Section V: Market Trends

13. Mergers and Acquisitions

14. Clinical Trial Analysis

15. Future Trends and Opportunities

Section VI: Market Forecast and Opportunity Analysis

16. SWOT Analysis

17. Global Medical Device CRO Market

18. Medical Device CRO Market, by Class of Medical Device

19. Medical Device CRO Market, by Type of Medical Device

20. Medical Device CRO Market, by Scale of Operation

21. Medical Device CRO Market, by Type of Preclinical Service Offered

22. Medical Device CRO Market, by Type of Clinical Service Offered

23. Medical Device CRO Market, by Company Size

24. Medical Device CRO Market, by Type of Original Equipment Manufacturer

25. Medical Device CRO Market, by Target Indication

26. Medical Device CRO Market, by Geographical Regions

27. Medical Device CRO Market, by Leading Players

Section VII: Case Study

28. Medical Device Developer and CRO Relationships: Key Value Drivers and Performance Indicators

29. Total Cost of Ownership for Medical Devices CROs

30. Case Study: List of Additional Medical Device CROs

Section VIII: Other Exclusive Insights

31. Conclusion

32. Executive Insights

Section IX: Appendices

33. Appendix I: Tabulated Data

34. Appendix II: List of Additional Medical Device Clinical CROs

35. Appendix III: List of Companies and Organizations

A selection of companies mentioned in this report includes, but is not limited to:

  • 1MED
  • 4Clinics
  • 4Pharma
  • A+ Science
  • Abiogenesis Clinpharm
  • Abond CRO
  • Absorption Systems
  • ABX-CRO
  • Acceliant
  • Accell Clinical Research
  • AccelLAB
  • Accelovance
  • Accredited Consultants
  • AccuLab Life Sciences
  • Accuprec Research Labs
  • Accutest Research Laboratories
  • Acorn Regulatory
  • Acrapack
  • acromion
  • aCROss Medical
  • ACT FARMA CRO
  • Activa Cro
  • ADAX International
  • Advanced Drug Development Services
  • Advanced Medical Research
  • Advena
  • Affinity Bio Partners
  • Afortiori Development
  • Afra Pharma Consultant
  • Aginko Research
  • AICROS
  • CETERA
  • AIX Scientifics
  • AJW Technology Consultants
  • AKRN
  • Al Tamimi & Company
  • Alera Labs
  • Alira Health
  • Allied Clinical Management
  • Altair Clinical
  • Altasciences
  • Altiora
  • AlvaMed
  • Amarex
  • American Preclinical Services (Acquired by NAMSA)
  • and many, many more!

For more information about this report visit https://www.researchandmarkets.com/r/ckgb1w

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Market Opportunity
Cronos Logo
Cronos Price(CRO)
$0,09536
$0,09536$0,09536
+0,61%
USD
Cronos (CRO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Bitcoin Has Taken Gold’s Role In Today’s World, Eric Trump Says

Bitcoin Has Taken Gold’s Role In Today’s World, Eric Trump Says

Eric Trump on Tuesday described Bitcoin as a “modern-day gold,” calling it a liquid store of value that can act as a hedge to real estate and other assets. Related Reading: XRP’s Biggest Rally Yet? Analyst Projects $20+ In October 2025 According to reports, the remark came during a TV appearance on CNBC’s Squawk Box, tied to the launch of American Bitcoin, the mining and treasury firm he helped start. Company Holdings And Strategy Based on public filings and company summaries, American Bitcoin has accumulated 2,443 BTC on its balance sheet. That stash has been valued in the low hundreds of millions of dollars at recent spot prices. The firm mixes large-scale mining with the goal of holding Bitcoin as a strategic reserve, which it says will help it grow both production and asset holdings over time. Eric Trump’s comments were direct. He told viewers that institutions are treating Bitcoin more like a store of value than a fringe idea, and he warned firms that resist blockchain adoption. The tone was strong at times, and the line about Bitcoin being a modern equivalent of gold was used to frame American Bitcoin’s role as both miner and holder.   Eric Trump has said: bitcoin is modern-day gold — unusual_whales (@unusual_whales) September 16, 2025 How The Company Went Public American Bitcoin moved toward a public listing via an all-stock merger with Gryphon Digital Mining earlier this year, a deal that kept most of the original shareholders in control and positioned the new entity for a Nasdaq debut. Reports show that mining partner Hut 8 holds a large ownership stake, leaving the Trump family and other backers with a minority share. The listing brought fresh attention and capital to the firm as it began trading under the ticker ABTC. Market watchers say the firm’s public debut highlights two trends: mining companies are trying to grow by both producing and holding Bitcoin, and political ties are bringing more headlines to crypto firms. Some analysts point out that holding large amounts of Bitcoin on the balance sheet exposes a company to price swings, while supporters argue it aligns incentives between miners and investors. Related Reading: Ethereum Bulls Target $8,500 With Big Money Backing The Move – Details Reaction And Possible Risks Based on coverage of the launch, investors have reacted with both enthusiasm and caution. Supporters praise the prospect of a US-based miner that aims to be transparent and aggressive about building a reserve. Critics point to governance questions, possible conflicts tied to high-profile backers, and the usual risks of a volatile asset being held on corporate balance sheets. Eric Trump’s remark that Bitcoin has taken gold’s role in today’s world reflects both his belief in its value and American Bitcoin’s strategy of mining and holding. Whether that view sticks will depend on how investors and institutions respond in the months ahead. Featured image from Meta, chart from TradingView
Share
NewsBTC2025/09/18 06:00
Nasdaq-listed iPower reaches $30 million convertible note financing agreement to launch DAT strategy.

Nasdaq-listed iPower reaches $30 million convertible note financing agreement to launch DAT strategy.

PANews reported on December 23 that, according to Globenewswire, Nasdaq-listed e-commerce and supply chain platform iPower announced it has reached a $30 million
Share
PANews2025/12/23 22:19
DOGE ETF Hype Fades as Whales Sell and Traders Await Decline

DOGE ETF Hype Fades as Whales Sell and Traders Await Decline

The post DOGE ETF Hype Fades as Whales Sell and Traders Await Decline appeared on BitcoinEthereumNews.com. Leading meme coin Dogecoin (DOGE) has struggled to gain momentum despite excitement surrounding the anticipated launch of a US-listed Dogecoin ETF this week. On-chain data reveals a decline in whale participation and a general uptick in coin selloffs across exchanges, hinting at the possibility of a deeper price pullback in the coming days. Sponsored Sponsored DOGE Faces Decline as Whales Hold Back, Traders Sell The market is anticipating the launch of Rex-Osprey’s Dogecoin ETF (DOJE) tomorrow, which is expected to give traditional investors direct exposure to Dogecoin’s price movements.  However, DOGE’s price performance has remained muted ahead of the milestone, signaling a lack of enthusiasm from traders. According to on-chain analytics platform Nansen, whale accumulation has slowed notably over the past week. Large investors, with wallets containing DOGE coins worth more than $1 million, appear unconvinced by the ETF narrative and have reduced their holdings by over 4% in the past week.  For token TA and market updates: Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here. Dogecoin Whale Activity. Source: Nansen When large holders reduce their accumulation, it signals a bearish shift in market sentiment. This reduced DOGE demand from significant players can lead to decreased buying pressure, potentially resulting in price stagnation or declines in the near term. Sponsored Sponsored Furthermore, DOGE’s exchange reserve has risen steadily in the past week, suggesting that more traders are transferring DOGE to exchanges with the intent to sell. As of this writing, the altcoin’s exchange balance sits at 28 billion DOGE, climbing by 12% in the past seven days. DOGE Balance on Exchanges. Source: Glassnode A rising exchange balance indicates that holders are moving their assets to trading platforms to sell rather than to hold. This influx of coins onto exchanges increases the available supply in…
Share
BitcoinEthereumNews2025/09/18 05:07